Source: International Congress 2018 – Innovative therapies in asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Rowe (Birmingham, United States of America), N. Haque (Cambridge, United States of America), S. Gleason (Cambridge, United States of America), I. Jones (Cambridge, United States of America), K. Kulmatycki (Cambridge, United States of America), D. Rowlands (Cambridge, United States of America), S. Grant (Cambridge, United States of America). A randomized, placebo controlled 4-week study in COPD of QBW251, a potentiator of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. 617

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study Source: Eur Respir J, 59 (2) 2100746; 10.1183/13993003.00746-2021 Year: 2022 Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis Source: Eur Respir Rev 2013; 22: 58-65 Year: 2013 Cystic fibrosis transmembrane conductance regulator pharmacotherapy Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=88 Year: 2006 Effects of the CFTR potentiator, ivacaftor, in two phase 3 trials in subjects with CF who have the G551D-CFTR mutation Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new therapies and detection of early lung disease Year: 2012 Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis Source: Eur Respir J 2011; 37: 59-69 Year: 2011 A three miRNA signature regulates the CF transmembrane conductance regulator (CFTR) in cystic fibrosis airway epithelium Source: Annual Congress 2011 - Epithelial cells: role in health and disease Year: 2011 The cystic fibrosis transmembrane conductance regulator and its modulators: clinical implications Source: Virtual Congress 2020 – Respiratory infections Year: 2020 How organoids helped to discover cystic fibrosis transmembrane conductance regulator (CFTR) therapeutics and predict response to treatment Source: International Congress 2016 – Closing the gap: novel translational research strategies Year: 2016 Nasal high-flow therapy (NHFT) during exercise in patients with cystic fibrosis (CF): a randomized crossover trial Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function Source: Eur Respir J 2011; 37: 1076-1082 Year: 2011 Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID) Source: Breathe, 17 (3) 210088; 10.1183/20734735.0088-2021 Year: 2021 CFTR biomarkers: time for promotion to surrogate end-point Source: Eur Respir J 2013; 41: 203-216 Year: 2013 Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator (CFTR) ion transport Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science Year: 2013 Atypical cystic fibrosis Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=38 Year: 2006 Channelopathies in bronchiectasis Source: Eur Respir Mon 2011; 52: 150-162 Year: 2011 Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient Source: Eur Respir J 2002; 19: 374-376 Year: 2002 A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1801992; 10.1183/13993003.01992-2018 Year: 2019 Azithromycin for cystic fibrosis Source: Eur Respir J 2004; 24 : 834-838 Year: 2004 Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation Source: Eur Respir Rev 2013; 22: 66-71 Year: 2013 The cystic fibrosis transmembrane conductance regulator: state of the art Source: Breathe 2008; 5: 163-167 Year: 2008